Scientific Industries (SCND) investor relations material

Executive summary

• Completed divestiture of the Genie products division in August 2025, resulting in a $5.26 million gain and marking a strategic pivot toward core growth areas.

• Focused on expanding the Torbal division and innovating the VIVID pill counter portfolio, including the launch of a new AI-driven feature.

• Bioprocessing segment concentrated on completing the DOTS platform and refining its core components for market fit.

• Net revenues for Q3 2025 increased 5.2% year-over-year to $1,404,000, driven by higher Torbal division sales, while Bioprocessing Systems revenues declined due to market softness and order delays.

• Positioned to benefit from the AI-driven transformation in pharma, synthetic biology, and research sectors.

Financial highlights

• Q3 was the strongest revenue quarter of 2025, with sales over 50% higher than Q2 and a 5.2% year-over-year increase to $1,404,000.

• Gross profit margin for Q3 2025 was 45.5%, down from 51.0% in Q3 2024, mainly due to the absence of Genie Division sales and higher material costs.

• Achieved third consecutive quarter of sequential growth, indicating gradual improvement in buying activity.

• Year-to-date lead generation up 22% compared to last year.

• Other income for Q3 2025 was $5,526,900, up from $78,500 in Q3 2024, primarily due to the Genie Division sale.

Outlook and guidance

• Expecting a challenging and highly selective capital spending environment through 2026.

• Management expects continued negative cash flows from operations in the foreseeable future but believes current cash and investments, bolstered by the Genie Division sale, are sufficient to fund operations for at least one year.

• R&D efforts focused on completing pH sensing technology for pilot projects in Q1 2026 and commercial launch later that year.

• Confident in long-term growth due to expanding platform, loyal customer base, and increasing strategic interest.